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Original Articles
Physiologically Based Pharmacokinetics of Molecular
Imaging Nanoparticles for mRNA Detection
Determined in Tumor-Bearing Mice
Armin W. Opitz,1 Eric Wickstrom,2 Mathew L. Thakur,3 and Norman J. Wagner1
Disease detection and management might benefit from external imaging of disease gene mRNAs. Previously we
designed molecular imaging nanoparticles (MINs) based on peptide nucleic acids complementary to cancer gene
mRNAs. The MINs included contrast agents and analogs of insulin-like growth factor 1 (IGF-1). Analysis of MIN
tumor uptake data showed stronger binding in tumors than in surrounding tissues. We hypothesized that MINs
with an IGF-1 analog stay in circulation by binding to IGF-binding proteins. To test that hypothesis, we fit the
tissue distribution results of several MINs in xenograft-bearing mice to a physiological pharmacokinetics model.
Fitting experimental tissue distribution data to model-predicted mass transfer of MINs from blood into organs
and tumors converged only when the parameter for MINs bound to circulating IGF-binding proteins was set to
10%–20% of the injected MIN dose. This result suggests that previous mouse imaging trials used more MINs
than necessary. This prediction can be tested by a ramp of decreasing doses.
Introduction
Reliable, noninvasive, early detection of cancer in hu-mans remains a significant challenge ( Jemal et al., 2007).
In particular, survival rates for pancreatic cancer might be
increased by early detection. Consequently, there has been
significant interest in developing molecular imaging nano-
particles (MINs) that can bind to mRNA inside cancerous
cells with high fidelity and be detected noninvasively by
methods such as positron emission tomography or magnetic
resonance imaging (Wickstrom et al., 2004; Basilion et al.,
2005; Chakrabarti et al., 2007; Amirkhanov et al., 2008).
MINs constructed from complementary peptide nucleic
acid–peptide chimeras can be used to detect overexpressed
oncogene mRNA when a contrast or imaging agent is at-
tached to the chimera (Tian et al., 2003, 2004, 2005a, 2005b)
(Fig. 1).
The specificity of the MINs has been demonstrated ex-
perimentally, where the MINs will distribute in the organs
and tissues of the body and will remain in the tumor target
while otherwise being filtered from the blood by the kidney
(Tian et al., 2003, 2004, 2005a, 2005b; Wickstrom et al., 2004;
Chakrabarti et al., 2007; Amirkhanov et al., 2008). The in vivo
experiments record the concentration of the MINs in the
organs of the mouse at a limited number of time points,
because of the need to sacrifice several mice to perform each
measurement. Pharmacokinetic modeling of the experimen-
tal data provides a method to extract a more complete pic-
ture of the fate of the MINs from the limited experimental
data. It also provides a rational method for experimental
design and optimization, as well as a promise to enable
translation across species, and maybe even prediction of ef-
ficacy in humans.
We developed a pharmacokinetic model for the distribu-
tion of the MINs in the mouse and applied it to the analysis
of experimental data sets. To our knowledge there is no
physiologically based pharmacokinetic model for peptide–
oligonucleotide chimeras in the literature. A physiologically
based model has been developed for oligonucleotide phar-
macokinetics in rats (Peng et al., 2001). We translated the rat
model to a mouse model to describe the pharmacokinetic
behavior of our MINs.
Different variants of the imaging nanoparticle have been
synthesized to target specific genes, while keeping the insulin-
like growth factor (IGF-1) peptide analog as the pathway to
enter the cells of the tumor. The different variants whose
pharmacokinetic behavior will be investigated here (Tian
et al., 2003, 2004, 2005a, 2005b) are shown in Table 1, along
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with the targeted gene. For clarity, we refer to each dataset
according to the target oncogene and year of publication (i.e.,
CCND1’04, MYCC’05, MYCC’03, KRAS’05) (Table 1).
The data analyzed herein were obtained by injecting 0.2ml
of a saline solution containing radioactive imaging nano-
particles into immunocompromised mice bearing a human
cancer xenograft carrying the KRAS, MYCC, or CCND1
mutation being targeted. At chosen times the mice were
lightly anesthetized and imaged to determine accumulation
of radioactivity. Following imaging, the mice were eutha-
nized and tissues were dissected. The tissue distribution of
radioactivity was originally reported as an average percent-
age of the injected dose per gram of tissue for fivemice at each
time point (Tian et al., 2003, 2004, 2005a, 2005b).
The peptide analog portion of the MINs, used to facilitate
endocytosis, is based on IGF-1, which plays an active role in
many illnesses and cancers ( Juul, 2003). Free IGF-1 is found in
the bloodstream, as well as IGF-1 bound to a variety of
insulin-like growth factor-binding proteins (IGFBPs) (Dela-
fontaine et al., 2004), which act as transporters and storage
pools (Bastian et al., 1997, 1999; Paye and Forsten-Williams,
2006; Forsten-Williams et al., 2007). Free IGF-1 not bound to
IGFBPs is reported to have a short half-life in blood, *10
minutes, similar to insulin (Sara andHall, 1990; Gillespie et al.,
1996; Mizuno et al., 2001; Juul, 2003). Bound IGF-1 can enter
an organ’s interstitial space, where upon binding proteins
release IGF-1, which then enters the tissue (Boroujerdi et al.,
1994, 1997). Preliminary work done on MIN tissue distribu-
tion in mice has shown that the MINs interact with the
IGFBPs, showing behavior similar to that of IGF-1. On the
basis of our experience to date (Tian et al., 2007; Opitz, 2008),
we anticipate that only 10%–20% of the injected dose is
available for distribution. The blood level of IGFBP-3 has been
reported to be 45 nmol=l in humans (Baxter andMartin, 1986).
We assume that a similar concentration occurs in mice, be-
cause the concentration of IGF-1 is similar in humans and
mice (Crispens, 1975a; Faria et al., 1989). Despite the existence
of numerous studies of oligonucleotide tissue distribution and
plasma clearance, there are very few studies attempting to
describe the tissue behavior quantitatively. Themost relevant,
physiologically based pharmacokinetic model for this study is
a permeability rate-limited model for a phosphorothioate ol-
igonucleotide targeting an initiation codon domain in the
herpes simplex virus, administered to rats (Peng et al., 2001),
which was shown to capture the tissue distribution of the
oligonucleotide over 72 hours.
Methods
The blood compartment in the Peng model is split into
venous and arterial blood compartments, while all organs are
described by a vascular compartment that is attached to an
extravascular compartment.
We adapted the Peng model to fit MIN tissue distribution
data. The intestine was split into large and small intestine
compartments. However, only the large intestine was mea-
sured in the tissue distribution studies. A tumor compartment
was added. Further, the adipose tissue, skin, bone, brain,
testes, and thymus were lumped together into one compart-
ment to account for MINs that accumulated in tissues not
measured in the experiment. The flow chart used for this work
is shown in Figure 2.
Equations 1–4 describe MIN concentration in the different
compartments. The variables are C, concentration of the com-
pound (mg=g); V, volume (ml); Q, flow rate (ml=hour); PS,
permeability surface area product (ml=hour); Kpu, extravas-
cular tissue=unbound plasma partition coefficient; Kp, equilib-
rium tissue=plasma partition coefficient (Kp¼ fKpu); f,
scaling factor from Peng et al. (2001); CLuki, renal clearance
(ml=hour); T,V, vascular part of a given tissue; T,EV, extravas-
cular part of a given tissue. The parameters KpuT and PST refer
to the respective parameter for a given tissue, e.g. Kpustomach,
PSstomach Kpukidney, PSstomach, and similarly for all other tissues
FIG. 1. (a) A molecular imaging nanoparticle consists of a
peptide, an insulin-like growth factor 1 (IGF-1) analog, which
is used to facilitate uptake of the imaging nanoparticle into the
cancer cells, a flexible hydrophilic spacer, a complementary
peptide nucleic acid (PNA) to bind specifically to the mutated
mRNA, a flexible hydrophilic spacer, and chelators for metal
cation contrast agents, shown with Gdþ3 for magnetic reso-
nance imaging contrast. (b) Molecular dynamics snapshot of
the molecular imaging nanoparticles after equilibration,
shownwith single chelator for positron emission tomography
contrast agent 64Cu (Chakrabarti et al., 2007).
Table 1. List of Imaging Nanoparticles Investigated,
Along with the Targeted Gene
Reference Gene targeted Peptide analog
Tian et al. (2005a) MYCC IGF-1
Tian et al. (2005b) KRAS IGF-1
Tian et al. (2004) CCND1 IGF-1
Tian et al. (2003) MYCC IGF-1
IGF-1, insulin-like growth factor 1.
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considered here. Of particular interest to this work was
Kputumor and PStumor. The parameters appearing in these equa-
tions are shown in Figure 2b, where a typical organ contains a
vascular compartment that is connected to the arterial and ve-
nous blood flow, and to the extravascular compartment
through a permeability parameter and a partition coefficient.
Each compartment is assumed to be well mixed. The Peng
model was implemented in MATLAB (The MathWorks, Inc.)
using the ode15s, ordinary differential equation solver.
Vven
dCvenðtÞ
dt
¼ ðQvenCvenðtÞÞ þ
X
i
QiCiðtÞ ð1Þ
Vart
dCartðtÞ
dt
¼ ðQartCartðtÞÞ þ ðQartCluðtÞÞ ð2Þ
VT,V
dCT,VðtÞ
dt
¼ ðQT þ ð f ·PSTÞÞCT,VðtÞ þ PST
KpuT
CT,EVðtÞ
þQTCartðtÞ ð3Þ
VT,EV
dCT,EVðtÞ
dt
¼ f ·PST CT,VðtÞ þ PST
KpuT
CT,EVðtÞ ð4Þ
The tissue distribution data, published as a percentage of
the injected dose per gram of tissue (Tian et al., 2003, 2004,
2005a, 2005b), were converted to micrograms of MIN per
gram of tissue, accounting for the varying specific activities
(Table 2). The initial blood concentrations (Table 2) upon in-
jection were calculated from the injected doses, assuming the
total mass of blood to be 1.68 g (7% of body mass).
The compound-specific parameters (Peng et al., 2001) were
adjusted to fit the measured tissue distribution data, whereas
the organ-specific parameters were changed to those of the
mouse. The different organ sizes and flow rates that were
used for the mouse are shown in Table 3, with the source of
each value indicated. Venous blood mass was assumed to be
twice the arterial blood mass (Gearhart et al., 1990; Quick and
Shuler, 1999). To determine the mass of the large intestine, the
typical length of the organ (ten Hove et al., 2002) was multi-
plied by a factor of mass per length for the large intestine in
themouse (Melgar et al., 2005). Themass of the small intestine
was determined by subtracting the weight of the large intes-
tine from the weight of the mouse gastrointestinal (GI) tract
(Lindstedt and Schaeffer, 2002). The muscle mass of the
mouse was taken from a graph detailing the body composi-
tion of mammals as a function of weight (Calder, 1984). The
thymus and the testes were given the same fraction of total
mass as used for the rat model (Peng et al., 2001).
The blood flow rate through the lung was set equal to the
flow rate of the venous and arterial blood compartments, as
for the rat (Peng et al., 2001). For the spleen blood flow rate,
only the plasma flow rate could be found (Gerlowski and Jain,
1983), which was divided by 0.55 (plasma=blood ratio) (Bax-
ter et al., 1994) to obtain the blood flow rate. The blood flow
rates of the thymus, bone, and adipose tissuewere set to be the
same fraction of the total blood flow rate for the rat (Peng et al.,
2001). The hepatic blood flow rate of the liver, the renal blood
flow rate of the kidney, and the blood flow rate of the muscles
were taken from the allometric relations (Lindstedt and
Schaeffer, 2002). The blood flow rate of the muscle was ad-
justed to ensure that the sum of the blood flow rates satisfied
an overall mass balance of the blood.
The fraction of extravascular space was taken from the rat
model (Peng et al., 2001), whichwas adapted from earlier data
(Everett et al., 1956; Ebling et al., 1994; Blakey et al., 1997). The
vascular space of the tumor was estimated to be about 15% of
the total weight of the tumor, based on an average of different
literature values for various tumors (Hilmas and Gillette,
1974; Jain, 1988; Kallinowski et al., 1989; Yuan et al., 1993).
This is reasonable because the xenografts used in the experi-
ments (Tian et al., 2003, 2004, 2005a, 2005b) formed aggressive
cancers, but did not reach a size where necrosis was apparent.
The values of KpuT, partition coefficient, and PST, tissue
FIG. 2. (a) Flow chart showing the organs considered in
this work; gray organs were included in the model but not
measured in the experiment. (b) Schematic of a typical organ
as part of the physiologically based model. C, concentration
of the compound (mg=g); V, volume (ml); Q, flow rate
(ml=hour); PS, permeability surface area product (ml=hour);
Kpu, extravascular tissue=unbound plasma partition coeffi-
cient; T,V, vascular part of a given tissue; T,EV, extravascular
part of a given tissue; Cven, concentration in venous com-
partment; Cart, concentration in arterial compartment.
Table 2. Doses of Molecular Imaging Nanoparticles
for the Different Studies
References Gene targeted mg mg=g
Tian et al. (2005a) MYCC 0.42 0.25
Tian et al. (2005b) KRAS 0.42 0.25
Tian et al. (2004) CCND1 0.43 0.26
Tian et al. (2003) MYCC 0.11 0.07
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permeability surface area product, taken from the rat model
(Peng et al., 2001), are shown in Table 4.
In total, the model has 32 tissue masses, 18 flow rates, 15
partition coefficients, and 1 clearance rate. All of the param-
eters except PST and KpuT for the tumor were determined
from independent literature values or by direct incorporation
of parameters determined for an oligonucleotide in rats (Peng
et al., 2001). The tissue and blood measurements of the MINs
were compared with the results of the 38 independent equa-
tions describing the different compartments to determine the
quality of the prediction. The main input parameter that was
varied is the fraction of the initial dose that is available to
distribute in the mouse. Once the behavior of the organs was
accurately described, the tumor data were incorporated. For
the tumor, the PStumor andKputumor valueswere varied until a
satisfactory fit was accomplished.
Results
The physiologically based rat model for oligonucleotide
pharmacokinetics (Peng et al., 2001) was adapted for MIN
distribution in the mouse by introducing the physiological
parameters aforementioned, while holding the permeation
rates fixed. The prediction was compared against the MIN
blood concentration of the CCND1’04 data. Using 10% of the
injected dose as the concentration available for distribution in
the body, based on our earlier analyses (Tian et al., 2007;
Opitz, 2008) that the MINs bind to IGFBPs to stay in circula-
tion, we were able to describe the CCND1’04 data by fitting to
the 24-hour time point. The other variants of theMINs behave
similarly; the KRAS’05 and MYCC’05 data have been cap-
tured well, as shown in Figure 3. However, the MYCC’05
dataset had a substantially lower injection dose (Table 5) and,
hence, was fit by a larger bound fraction (20%), as hypothe-
sized.
The predictions using 10%–20% of the actual injected dose
capture the behavior of the different variants of the MINs in
the blood. The predictions for MIN concentrations in the
different organs are shown in Figure 4, for the CCND1’04
Table 3. Physiological Parameters for the Mouse
Tissue
Vascular
(g)
Extravascular
(g) Flow rate (ml=hour)
Venous 1.12 1.12 (Wish et al., 1950; Crispens, 1975a) 589.09 (Gjedde and Gjedde, 1980;
Sarin et al., 1990; Lindstedt and
Schaeffer, 2002; Kober et al., 2004)
Arterial 0.56 0.56 (Wish et al., 1950; Crispens, 1975a) Same as venous compartment
Lung 0.04 0.11 0.14 (Plata and Murphy, 1972;
Crispens, 1975b)
589.09 (Peng et al., 2001)
Stomach 0.02 0.10 0.12 (Barnett and Widdowson, 1965) 11.66 (Stott et al., 1983)
Spleen 0.02 0.06 0.08 (Tsai et al., 2002) 5.45 (Gerlowski and Jain, 1983;
Baxter et al., 1994)
Small intestine 0.09 0.64 0.73 (Lindstedt and Schaeffer, 2002) 79.53 (Stott et al., 1983)
Large intestine 0.02 0.12 0.14 (ten Hove et al., 2002;
Melgar et al., 2005)
21.62 (Stott et al., 1983)
Muscle 0.24 8.82 9.06 (Calder, 1984) 153.70 (Lindstedt and
Schaeffer, 2002)
Adipose 0.12 0.68 0.80 (Marningas et al., 1986) 25.15 (Peng et al., 2001)
Skin 0.07 3.74 3.82 (Lindstedt and Schaeffer, 2002) 34.64 (Stott et al., 1983)
Bone 0.04 1.05 1.09 (Lindstedt and Schaeffer, 2002) 33.09 (Peng et al., 2001)
Heart 0.01 0.10 0.11 (Lindstedt and Schaeffer, 2002) 40.85 (Stott et al., 1983;
Barbee et al., 1992)
Thymus 0.00 0.06 0.06 (Peng et al., 2001) 4.24 (Peng et al., 2001)
Brain 0.02 0.49 0.51 (Lindstedt and Schaeffer, 2002) 31.81 (Stott et al., 1983)
Testes 0.00 0.25 0.25 (Peng et al., 2001) 2.47 (Stott et al., 1983)
Liver 0.11 0.83 0.93 (Lindstedt and Schaeffer, 2002) 20.13 (Lindstedt and Schaeffer, 2002)
Kidney 0.03 0.22 0.25 (Tsai et al., 2002) 107.05 (Lindstedt and Schaeffer, 2002)
Tumor 0.11 0.60 0.71 (Chakrabarti et al., 2007) 17.67 (Raczka et al., 1983)
Table 4. Tissue=Blood Distribution Coefficients
and Permeability Surface Area Products
Tissue KpuT PST (ml=hour)
Lung 26.38 2.48
Stomach 13.43 2.38
Spleen 57.52 4.67
Small intestine 22.86 31.81
Large intestine 22.86 31.81
Muscle 8.95 68.19
Adipose 6.29 6.38
Skin 9.24 87.14
Bone 25.05 162.86
Heart 12.19 2.95
Thymus 8.19 13.05
Brain 8.48 0.29
Testes 16 1.71
Liver 120.95 96.19
Kidney 369.52 44.67
Tumor 20 5
Clearance 2.11 (ml=hour)
f 0.105
Bold values are results of the model fitting.
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data. The data shown are representative of those for the other
MIN variants; graphs for the other variants are shown in the
Supplemental Material (available online at www.liebertonline
.com) (Supplemental Figs. S1–S3, available online at www
.liebertonline.com). Predictions for MIN concentrations in
most of the organs are excellent, with the exception of the
spleen and kidney. The discrepancy for the spleen is due to
difficulty of determining the proper volume from the litera-
ture. The kidney is underpredicted, as it filters the unbound
MINs from the blood. These results are consistent with the
hypothesis that the imaging nanoparticles need to bind to the
IGFBPs to remain in the blood.
For the tumor, PStumor and Kputumor were fit to the exper-
imental data. A best fit to the data was obtained with
Kputumor¼ 20 and PStumor¼ 5. The predictions using these
values for all the other MIN variants are shown in Figure 5.
Overall, the physiologically based model can satisfactorily
describe the time course behavior of the tissue, and in partic-
ular the tumor, distribution of the variants of MINs with one
common set of transport and partition values. A sensitivity
analysis of the fit in response to the value of the permeability
surface area product, based on the work by Schmittmann and
Rohr (2000), shown in the Supplemental Material, shows that
the results are robust to variations in the PST values.
One set of parameters for permeability and distribution
(Table 4) can represent all four MIN variants, showing that
variation in oligonucleotide sequence does not affect trans-
port, as expected. To assess whether the parameters obtained
from the best fit to the tumor concentration data are mean-
ingful it is useful to compare them to the parameters de-
scribing other tissues. Comparing organs that have a similar
value of Kpu, the distribution coefficient, such as the intes-
tines and bone as shown in Table 4, the permeability area
product is smaller for the tumor. This can be explained by a
lower blood flow rate in the tumor compared to those organs.
To evaluate the distribution coefficient Kpu for the tumor, it
can be compared to Kpu for the muscles, as it was implanted
in the muscles. The Kpu for the tumor was higher than the
value for the muscles, which could indicate stronger binding
in the tumor. If the MIN accumulates and binds in the tumor
by the antisense modality, it would lead to a comparatively
higher Kpu value. This comparison can also be made through
the PST=KpuT ratio for the tumor and other organs, as shown
in Table 6. Comparing the ratio for the tumor to that of the
muscle, the tumor ratio is much smaller. This implies a very
large distribution coefficient in relation to its permeability,
which again supports the notion of the MIN binding in the
tumor. We caution, however, that because the model does not
explicitly account for antisense binding to the RNA, phar-
macokinetic parameters derived fromfitting the data aremost
likely compensating for this effect.
Discussion
The time course of MIN tissue distribution in mice was
modeled using the kinetic and distribution parameters de-
veloped for a rat model (Peng et al., 2001), adjusted for mouse
FIG. 3. Normalized blood concentration predictions for all
different imaging nanoparticle variants.
FIG. 4. Normalized organ concentrations using CCND1’04
data, with reduced injection amount.
Table 5. Injected Molecular Imaging Nanoparticles
(nmol=l) in Plasma
nmol nmol=g nmol=l
% bound
to
IGFBP
CCND1, 2004 1.04 E 01 6.18 E 02 34 10
KRAS, 2005 9.58 E 02 5.70 E 02 31.4 10
MYCC, 2005 9.88 E 02 5.88 E 02 32.3 10
MYCC, 2003 3.08 E 02 1.83 E 02 10.1 20
IGFBP-3 (Baxter
and Martin, 1986)
— — 45
IGFBP, insulin-like growth factor binding proteins.
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organ volumes and flow rates. To fit the blood data, the in-
jected dose of the MINs had to be reduced by 80%–90%. This
is attributed to be a consequence of the need to bind to IGFBPs
to transport into the organs (Bastian et al., 1997, 1999; Paye
and Forsten-Williams, 2006). The modeling suggests that the
majority of the injected MINs are removed by renal clearance.
The majority of the MIN organ concentrations were pre-
dicted accurately, except for the kidney and the spleen. The
overprediction of the spleen concentrations may be due to
uncertainty in the estimated blood flow rate to the spleen in
the mouse, as the spleen flow rate has not been reported. The
concentration in the kidney was underpredicted due to the
likelihood of unexcreted MINs remaining in the organ.
The parameters describing the time course of the tumor
MIN concentration behaved as expected in comparison to the
parameters of other organs. To determine whether the mag-
nitude of the values obtained from fitting the tumor MIN
concentration is physiologically reasonable, the valuesmay be
compared with literature values describing uptake of com-
pounds into tumors. A pharmacokinetic model for benzo-
quinone anisamycin antibiotic, which is an antiproliferative
agent for tumors, yielded values derived from a similar model
(Xu et al., 2003). The model considered the tumor as three
compartments, vascular, interstitial, and cellular space;
equations 5 and 6 describe the former two compartments,
which are the equivalent of equations 3 and 4 shown for the
model used in this work.
VV
dCVðtÞ
dt
¼ QðCArt  CvÞ  PSV;ITðCV  CITÞ ð5Þ
VIT
dCITðtÞ
dt
¼ PSV;ITðCV  CITÞ  kIT;C CT;VðtÞ VIT
þ KC;IT CCðtÞVC ð6Þ
Comparing the permeability term from equation 6 to
equation 4, the equivalent term from equation 4 is the product
of f and PStumor. Thus the value of PStumor for this work is
0.525ml=hour, whereas the value reported for anisamycin
(Xu et al., 2003) was 0.227ml=hour. These comparisons
demonstrate that our value of the permeability surface area
product is physiologically reasonable.
As mentioned earlier, the specific binding behavior of the
MINs in the tumor was not accounted for in the modeling. To
assess whether the antisense modality plays a role in the
measured distribution of the MINs, the model results can be
examined for consistency. For example, a maximum concen-
tration in the tumor can be calculated, which should not be
exceeded if the MIN only binds to its mRNA target. Typical
breast or pancreas cancer cells in culture contain 2000–8000
copies of CCND1,MYCC, or KRASmRNA (Tian et al., 2005b).
Taking a cell diameter of approximately 10mm, and assuming
a density of 1 g=cm3, we estimate there are 2–81012 copies=g
or 0.003–0.013nmol=g of oncogenemRNA in the extravascular
space of each tumor, for each gene targeted. The measured
MIN concentrations and the total amount ofMINs delivered to
the tumor, as calculated from themodel, are shown in Table 7.
Using a molecular mass of 4.3103 g=mol, the estimated
maximum binding capacity of the oncogenes expressed in the
tumor is 0.014–0.054mg=g, which is greater than both the
measured MIN concentration as well as the total amount of
MINs delivered during the course of the experiment (Table 7).
Note that this is the amount delivered to the tumor’s vascular
space, not all of which is transferred into the tumor’s extra-
vascular space. Therefore, the model and this simple analysis
indicate that there are ample oncogene mRNA binding copies
available to accommodate the MINs delivered to the tumor.
Second, integrating the predicted time course up to the first
experimental time point will indicate if sufficient MINs enter
the tumor to account for the recorded concentration. The
value of the total amount delivered into the tumor at 4 hours is
indicated in Table 7, along with the amount measured ex-
perimentally in the tumor at 4 hours, the model-predicted
maximum concentration at the spike, and the total possible
concentration based on number of binding sites. Again, these
results are consistent with the antisense binding modality of
the MINs.
Table 6. Ratio of PST=KpuT for the Parameters
from Peng et al. (2001)
Tissue PST=KpuT
Lung 0.09
Stomach 0.18
Spleen 0.08
Small intestine 1.39
Large intestine 1.39
Muscle 7.62
Adipose 1.02
Skin 9.43
Bone 6.5
Heart 0.24
Thymus 1.59
Brain 0.03
Testes 0.11
Liver 0.8
Kidney 0.12
Tumor 0.25
FIG. 5. Normalized tumor concentration and physiological
model predictions for all imaging nanoparticle variants,
using reduced injection amounts. Kputumor¼ 20, PStumor¼
5ml=hour.
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The tissue distribution of several variants of the MIN, an
MIN with an antisense modality, was quantitatively modeled
using a physiologically based pharmacokinetic model. A
physiologically based oligonucleotide pharmacokinetic
model in rats (Peng et al., 2001) was adapted to a mouse
model to predict the tissue distribution of the MINs. This was
achieved by using measured and estimated physiological
parameters of the mouse with the tissue=blood distribution
coefficient and the permeability constant from the rat model
for an oligonucleotide probe. This resulted in a model with 64
parameters determined independent of the experimental
data, and only the unknown permeability and distribution
coefficient of the tumor were left as fit parameters. In fitting
the model to the experimental data, it was found that only
10%–20% of the injected MINs were available for transport
from the blood to the interstitial tissues. This result is con-
sistent with the IGF-1 modality of the MINs and the known
role of IGF-1-binding protein in facilitating transport. Rapid
elimination of the unbound chelator–peptide nucleic acid–
IGF-1 peptide analog probably occurs by first-pass kidney
excretion.
This result also suggests that previousmouse imaging trials
used moreMINs than necessary. This prediction can be tested
by a ramp of decreasing doses.
The parameters determined in this work for the tumorwere
shown to be consistent for all variants of the MINs investi-
gated, as well as physiologically reasonable given other re-
ported parameter sets for analogous probes.
This work demonstrates that a pharmacokinetic model
developed for a rat model could be adapted to quantitatively
model another species, which holds promise for describing
the behavior of the MINs in humans. Overall, a preliminary
model of MIN pharmacokinetics has been developed, which
can be adapted and expanded when a more complete time
course of the blood concentration and more time points of
tissue concentrations are available.
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